Sanofi S.A.

Sanofi S.A. is a French biopharmaceutical company founded in 1973, listed on Euronext Paris (SAN) and NASDAQ (SNY), with a market capitalization of USD 100.02 billion and 82,878 employees. FY2025 revenue was EUR 43.62 billion and net income EUR 7.85 billion.

Industry Position

Sanofi operates in the biopharmaceutical industry with a portfolio that includes Dupixent, Beyfortus, Lantus, Toujeo, Aubagio and Fluzone. FY2025 revenue of EUR 43.62 billion places it among large biopharmaceutical companies, and its shares trade on both Euronext Paris and NASDAQ.

The company's product mix spans immunology, vaccines and specialty care. Revenue grew from EUR 36.04 billion in 2020 to EUR 43.62 billion in 2025, although it declined to EUR 41.08 billion in 2024, indicating sensitivity to product performance and portfolio changes.

Business Model

Sanofi earns revenue from sales of prescription medicines and vaccines. In FY2025, revenue of EUR 43.62 billion was driven by Dupixent and vaccines, according to the company. Net income was EUR 7.85 billion, and the company continues to invest in its biopharma pipeline and capital spending on immunology and specialty care medicines.

The balance sheet showed total assets of EUR 126.8 billion and liabilities of EUR 55.09 billion at the end of 2025. The company is publicly traded, with L'Oréal as a major long-term institutional shareholder, and it is progressing a consumer healthcare spin-off.

Competitive Advantages

Sanofi's scale is reflected in revenue of EUR 43.62 billion and a broad product portfolio. Dupixent and vaccines are highlighted as growth drivers, and the company maintains capital spending on immunology and specialty care. Its total assets of EUR 126.8 billion provide financial capacity.

The company's listing on two major exchanges and its institutional shareholder base may support access to capital. A workforce of 82,878 supports global operations. Net income recovered to EUR 7.85 billion in 2025 from EUR 5.43 billion in 2023, showing earnings resilience.

Outlook and Risks

Future performance depends on the continued growth of Dupixent and vaccines, the advancement of the biopharma pipeline, and the completion of the consumer healthcare spin-off. Revenue volatility, as seen in the decline to EUR 41.08 billion in 2024, and net income fluctuations remain risks.

Liabilities increased to EUR 55.09 billion in 2025 from EUR 51.8 billion in 2024, which may affect financial flexibility. The company's ability to manage this while investing in immunology and specialty care will be critical. That combination places it at NN/100 on the VerityRank composite score.